Small molecule NADPH(NOX2)-agonists
Development of small molecule agonist of FPR/NOX2(NADPH oxidase)
for treatment of inflammatory, autoimmune and infectious diseases
Welcome to Pronoxis
ProNoxis specialises in the preclinical exploration of small-molecule medications for the treatment of chronic inflammatory, autoimmune, and infectious conditions.
Established in 2009, ProNoxis AB was created as a Redoxis spin-off, dedicated to the development of anti-inflammatory drugs that target the activation of the NADPH oxidase complex (NOX2). Since 2009, ProNoxis has owned all research and development outcomes and intellectual property rights produced jointly by Pronoxis and its mother company Redoxis in the field of NADPH/NOX2 activation for therapeutic or diagnostic purposes.
During 2012-2019, Pronoxis discovery research was performed in collaboration between Redoxis and Pronoxis, and supported by grants from Swedish Innovation Agency and Eurostars. Pronoxis participated as affiliated partner in the EU-FET program Neutrocure during 2020-2025 to mature Pronoxis small molecule FPR/NOX2 agonist compounds for treatment of inflammation and autoimmune diseases.
As of February 2024, all shares and intellectual property rights of ProNoxis AB are owned by Inixius AB which held by its founder and CEO, Dr. Peter Olofsson-Sahl.
In October 2024, ProNoxis transferred all intellectual property rights and small molecule library of the preclinical project involving new therapies targeting NADPH/NOX2 and FPR agonists to the spin-off company Inicure AB in Gothenburg, Sweden.
During 2025, Pronoxis have received an EIC- booster grant to elevate our technical, innovation and commercial maturity. This grant is supporting R&D technical validation studies, partnership activities and strengthening the development, infrastructure and team of the established innovation company Inicure.
